Stock Screener App

Gratuito -

Installare

Drug Manufacturers - Major

77.94

3.45% 2.60

after-market

Dopo l'orario di chiusura: 78.78 0.84 +1.08%

Astrazeneca PLC (AZN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Perché AZN Giù? Forum Previsione Frazionamento azionario Storia dei dividendi

Astrazeneca PLC Borsa (AZN) Ultime notizie

AstraZeneca’s Promising Phase 2b Study on AZD2373 for Kidney Disease - TipRanks

AstraZeneca’s CAPItello-292 Study: A New Hope for Advanced Breast Cancer Treatment - TipRanks

AstraZeneca’s Real-World Study on Acalabrutinib in CLL Patients: Key Insights for Investors - TipRanks

AstraZeneca’s Promising Phase I Study on Advanced Solid Tumors: Key Insights for Investors - TipRanks

AstraZeneca’s Promising Phase III Study on AZD0901 for Gastric Cancer - TipRanks

AstraZeneca’s Olaparib Study Completion: Implications for Investors - TipRanks

AstraZeneca's Young Health Programme Earns Top Industry Honor for Healthcare Leadership - Stock Titan

AstraZeneca, Stockholders Far Apart In Merger Damages Tally - Law360

AstraZeneca’s Phase 3 Study on Anifrolumab: A Potential Breakthrough for Lupus Treatment - TipRanks

AstraZeneca’s Phase III Study on Dato-DXd in Advanced Breast Cancer: Key Insights for Investors - TipRanks

AstraZeneca’s CRT Study in Russia: Implications for Lung Cancer Treatment - TipRanks

AstraZeneca’s iCaReMe Global Registry: A Game Changer in Real-World Data Collection - TipRanks

AstraZeneca’s Latest Study on Balcinrenone/Dapagliflozin: Key Insights for Investors - TipRanks

AstraZeneca’s Real-World Study on NSCLC Drugs: Key Insights for Investors - The Globe and Mail

AstraZeneca’s Real-World Study on Tezepelumab: Implications for Severe Asthma Treatment - TipRanks

AstraZeneca’s New CKD Study: A Strategic Move in the Chinese Market - TipRanks

AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Game-Changer in Cardiovascular Health - TipRanks

AstraZeneca Sees Slight Change in Voting Rights by Capital Group - TipRanks

Ascites Market Dynamics Indicate Upward Trajectory Through 2034, Reports DelveInsight | PharmaIN, AstraZeneca plc, Pfizer Inc., Novartis AG, Baxter International Inc., Becton, Dickinson and Company - The Globe and Mail

Revna Biosciences and AstraZeneca Increase Access to Lung Cancer Treatment in Ghana - sg.finance.yahoo.com

Gastric Cancer Market on Growth Trajectory: Novel Therapies Drive Momentum Through 2034 | DelveInsight - GlobeNewswire Inc.

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts - Benzinga

AstraZeneca’s PROGRESS-CKD Study: A New Frontier in Hypertension and Kidney Disease Research - TipRanks

AstraZeneca’s DESTINY-Lung03: A Promising Phase Ib Study in NSCLC - TipRanks

AstraZeneca’s Phase II Study on AZD9291: A Promising Update for NSCLC Treatment - TipRanks

AstraZeneca’s AZD9291 Trial: A New Hope for Lung Cancer Treatment? - TipRanks

AstraZeneca: Great Portfolio, But Not A Great Price (NASDAQ:AZN) - Seeking Alpha

AstraZeneca | Pharmaceuticals, Vaccines, & Facts - Britannica

AstraZeneca’s CARDIO-TTRansform Study: A Potential Game-Changer for ATTR CM Treatment - The Globe and Mail

AstraZeneca’s NeoCOAST-2 Study: A New Frontier in Lung Cancer Treatment - The Globe and Mail

AstraZeneca’s Andexanet Alfa Study: Real-World Insights for Investors - The Globe and Mail

AstraZeneca’s Real-World Study on Koselugo: Key Insights for Investors - The Globe and Mail

AstraZeneca’s Phase II Study on Olaparib in Ovarian Cancer: A Market Perspective - The Globe and Mail

AstraZeneca’s Anifrolumab Study: A Potential Game-Changer in Inflammatory Myopathies - TipRanks

AstraZeneca’s Promising Phase 2b Study on AZD2693 for NASH: Key Insights for Investors - TipRanks

AstraZeneca’s Phase III Study on Baxdrostat and Dapagliflozin: A Potential Game-Changer for CKD Treatment - TipRanks

AstraZeneca’s Latest NSCLC Study: A Potential Game-Changer? - The Globe and Mail

AstraZeneca’s AZD6234 Study: A Potential Game-Changer for Renal Impairment Treatment - TipRanks

AstraZeneca’s Phase I Study on AZD4954: A Potential Game-Changer in Cardiovascular Treatment - The Globe and Mail

AstraZeneca’s Anifrolumab Study: Real-world Insights into SLE Treatment - TipRanks

AstraZeneca’s ARTEMIDE-Lung03 Study: A New Frontier in NSCLC Treatment - TipRanks

AstraZeneca’s PANGEIA-2 Study: Unveiling New Insights in Breast Cancer Mutations - TipRanks

AstraZeneca’s TROPION-Lung05 Study: A New Hope for Advanced NSCLC - TipRanks

AstraZeneca’s New Trial: Exploring AZD8421 for Advanced Cancers - TipRanks

AstraZeneca’s Real-World Study on mCRPC Treatment: Key Insights for Investors - TipRanks

AstraZeneca’s New Study on TDC Treatment for mNSCLC: Key Insights for Investors - TipRanks

Inside AstraZeneca’s long-term strategy in lung cancer - BioPharma Dive

Swedish Shares in North America – AstraZeneca Rises 1.1 Percent - MarketScreener

AstraZeneca’s Promising Phase II Study on AZD6234: A Potential Game-Changer for Type 2 Diabetes - TipRanks

AstraZeneca’s New COPD Study: Potential Market Shifts Ahead - TipRanks

Amgen and AstraZeneca’s HORIZON Study: A New Hope for Pediatric Asthma - TipRanks

AstraZeneca’s Promising Study on Durvalumab for Advanced Biliary Tract Cancers - TipRanks

AstraZeneca’s New Study on AZD5004: Potential Market Implications - TipRanks

AstraZeneca’s Phase III Study on Advanced Liver Cancer: Key Insights for Investors - TipRanks

AstraZeneca’s Promising Study on Volrustomig for Mesothelioma: Key Insights for Investors - TipRanks

AstraZeneca’s TITANium Study: A New Hope for B-Cell Malignancies? - TipRanks

AstraZeneca’s New Phase III Study: A Potential Game-Changer in Lung Cancer Treatment? - TipRanks

AstraZeneca’s Phase 1 Study on AZD9833: A New Hope for Advanced Breast Cancer - TipRanks

AstraZeneca’s MaesTTRo Study: Real-world Insights into ATTR Amyloidosis - TipRanks

AstraZeneca’s New Study on Saruparib: A Potential Game-Changer in Prostate Cancer Treatment - TipRanks

AstraZeneca’s Study on ATTR PN in Russian CTS Patients: Key Insights for Investors - TipRanks

AstraZeneca’s COPD Study: Key Insights and Market Impact - TipRanks

AstraZeneca’s HK-QIP Study: A Step Forward in Hyperkalemia Management - TipRanks

AstraZeneca’s New Study on NSCLC Treatment Patterns: What Investors Need to Know - TipRanks

AstraZeneca’s Innovative Phase 1 Study Targets KRAS Mutations in Advanced Tumors - TipRanks

AstraZeneca’s New Study Aims to Revolutionize COPD Care - TipRanks

AstraZeneca’s New Study on Trastuzumab Deruxtecan: A Potential Game-Changer in Cancer Treatment - The Globe and Mail

AstraZeneca’s New Study on AZD6234: Implications for Renal Impairment Treatment - The Globe and Mail

AstraZeneca’s Myasthenia Gravis Study in China: Key Insights for Investors - TipRanks

AstraZeneca Advances NASH Research with New Clinical Study - TipRanks

September 26th Options Now Available For AstraZeneca (AZN) - Nasdaq

Apri su Yahoo | Apri su Google | Aperto in Finviz | Apri in MarketWatch | Aperto a EDGAR | Aperto su Reuters